Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Cefepime-taniborbactam trumps meropenem for complicated UTI
Cefepime-taniborbactam (FTB) is significantly better than meropenem for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), according to results of the Cefepime Rescue with Taniborbactam in cUTI (CERTAIN-1) study presented at the recent ID Week 2022.
Cefepime-taniborbactam trumps meropenem for complicated UTI
26 Oct 2022Silymarin reduces lesions, pain in women with endometriosis
Among women suffering from endometriosis, treatment with silymarin leads to lowered interleukin (IL)-6 concentrations, smaller endometrioma lesions, and eased pain, a recent study has found.
Silymarin reduces lesions, pain in women with endometriosis
26 Oct 2022Psychotic disorders a potentially modifiable risk factor for dementia
Individuals with nonaffective psychotic disorders appear to have a twofold higher risk of developing subsequent dementia compared with those who do not have such disorders, as reported in a recent study.
Psychotic disorders a potentially modifiable risk factor for dementia
25 Oct 2022Singaporeans’ affair with Western-style fast food: Unhealthy and possibly deadly
A diet heavy in Western-style fast food is known to make people fat and unhealthy, and a recent study quantifies its toll in an Eastern population, particularly Singaporeans: Frequent intake puts one at risk of developing type 2 diabetes (T2D) and dying from coronary heart disease (CHD).
Singaporeans’ affair with Western-style fast food: Unhealthy and possibly deadly
25 Oct 2022Brentuximab vedotin-chemo confers OS advantage over bleomycin-containing chemo for advanced HL
In the 6-year follow-up of the ECHELON-1 trial, a combination of the CD30-directed ADC* brentuximab vedotin and a chemotherapy (CT) regimen comprising doxorubicin, vinblastine, and dacarbazine (A+AVD), showed a survival advantage over a combination comprising the same CT regimen plus bleomycin (ABVD) in patients with previously untreated stage III or IV Hodgkin’s lymphoma (HL).